News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ImmunoGen, Inc. (IMGN) Grabs $84 Million



5/20/2011 8:25:51 AM

Waltham, MA-based ImmunoGen (NASDAQ: IMGN), the developer of targeted antibody drugs for cancer, said today it has raised $84 million through a stock offering. The company sold 7 million new shares at $12 apiece. Jefferies & Co., Oppenheimer & Co., RBC Capital Markets, William Blair & Co., Canaccord Genuity and Morgan Joseph TriArtisan managed the offering. ImmunoGen had $115.8 million in cash on hand at the end of March, according to its most recent quarterly report.

Read at Xconomy
Read at Forbes
Read at Mass High Tech


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES